Insulin Pump Wireless Telemetry Patents: Leaders & White Space 2026
A data-backed view of insulin pump wireless telemetry patents: who leads filings, how claims concentrate around A61M and A61N classes, and where the white space sits for new entrants in 2026.
Filing growth = 2021 (3 records) → 2024 (0); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 206 records in scope (CR5), not the ranked leaders only.
What insulin pump wireless telemetry patents actually cover
Insulin pump wireless telemetry sits at the intersection of drug-delivery hardware and data transmission: a pump body that infuses insulin, paired with a sensor or handheld device that reads glucose data and sends dosing instructions over a wireless link. The 206 records in scope span devices for body fluids (A61M), diagnostic and surgical claims (A61B), electrotherapy (A61N), and a substantial software layer under G06F and G16H. That spread means a single pump-and-sensor product can generate claims across four or five IPC subclasses at once, which is why the technology composition figures below add up to well over 100% of the record total.
The earliest heavily-cited records in this dataset are closed-loop infusion and ambulatory telemetry patents dating back well before the 2015 coverage window, which explains why citation counts favour those older filings over anything published in the last three years.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 206-record dataset: how filing activity has moved year over year, and how those records distribute across IPC subclasses.
Filing trend: a 2019 peak, then a falling tail
Filings rose from 5 in 2017 to a peak of 16 in 2019, then declined; the tracked 2021-to-2024 span shows a -100% change. 2025 and 2026 figures are not yet complete because publication lags filing by roughly 18 months, so the most recent bars understate real activity.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
Technology composition: hardware claims dominate, software is close behind
A61M (devices for body fluids) appears on 67.0% of the 206 records, A61B on 54.4%, and A61N on 45.6%. G06F and G16H each sit at 43.7%, meaning nearly half of all records also stake a data-processing or informatics claim alongside the physical pump.
Shares are the percentage of the 206 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Insulin Pump Wireless Telemetry Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about insulin pump wireless telemetry patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records and one representative filing
US8460243B2 — Glucose measuring module and insulin pump combination
A combination glucose measuring and insulin pumping device is described. The two major components, a glucose measuring module and an insulin pump, are held together by a quick attach and release mechanism. Communication between the glucose measuring module and the insulin pump is by a wireless modality. The glucose measuring module determines the glucose level in a sample, and wirelessly transmits the data to the insulin pump, where the data are stored in a memory, and are available for visual display on the insulin pump, and for incorporation into selection of appropriate protocols for the rate of insulin infusion by the pump into the patient.Filed by Smiths Medical ASD, Inc.; granted 2013-06-11.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5569186A | Closed loop infusion pump system with removable glucose sensor | 2,310 |
| 2 | US6694191B2 | Ambulatory medical apparatus and method having telemetry modifiable control software | 1,762 |
| 3 | US6122536A | Implantable sensor and system for measurement and control of blood constituent levels | 1,584 |
| 4 | US6810290B2 | Ambulatory medical apparatus with hand held communication device | 1,573 |
| 5 | US6740075B2 | Ambulatory medical apparatus with hand held communication device | 1,564 |
| 6 | US6585644B2 | Ambulatory medical apparatus and method using a telemetry system with predefined reception listening periods | 1,525 |
| 7 | US6562001B2 | Microprocessor controlled ambulatory medical apparatus with hand held communication device | 1,468 |
| 8 | US6873268B2 | Microprocessor controlled ambulatory medical apparatus with hand held communication device | 1,413 |
| 9 | US6577899B2 | Microprocessor controlled ambulatory medical apparatus with hand held communication device | 1,382 |
| 10 | US6571128B2 | Microprocessor controlled ambulatory medical apparatus with hand held communication device | 1,372 |
Citation counts reward older filings that have had more time to accumulate citations inside the searched corpus; treat them as a signal of influence on the field, not as a ranking of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the concentration and technology mix mean for filing strategy
Three findings from this dataset that matter for anyone deciding where to file or where to look for freedom to operate.
The top of the table is settled
Five assignees hold 59.2% of all 206 records in scope, and the top ten hold 80.1%. That leaves a long tail of 39 further ranked companies splitting the remainder — a pattern typical of a field with a small number of incumbents and many single- or few-filing entrants rather than a wide-open race.
Software claims run alongside the hardware
A61M pump-device claims lead at 67.0% of records, but G16H healthcare informatics and G06F data-processing each sit at 43.7%. A pump-only claim increasingly overlaps with a data-handling claim in the same family, so a freedom-to-operate search that stops at A61M will miss a large share of the relevant prior art.
Activity has cooled since its 2019 peak
Filings climbed from 5 in 2017 to a peak of 16 in 2019, then fell; the 2021-to-2024 window shows a -100% swing. Because publication lags filing by roughly 18 months, the 2025-onward figures are still incomplete and should not be read as proof the field has stopped moving.
The most-influential records predate the 2015 window
The most-cited records in this dataset, including closed-loop infusion and ambulatory telemetry patents, were granted well before 2015 and carry citation counts in the thousands. That reflects age and corpus visibility more than current relevance, and newer filings have not had time to accumulate comparable citation counts.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to insulin pump wireless telemetry patent landscape, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| MEDICAL RESEARCH GROUP INC | MINIMED INC | 6 |
| Thomas Jefferson University | CROTHALL KATHERINE D | 4 |
| THERASENSE INC | REGGIARDO CHRISTOPHER V | 2 |
| Thomas Jefferson University | Animas Corp | 2 |
| Medtronic MiniMed Inc | MEDICAL RESEARCH GROUP INC | 1 |
| REMON MEDICAL TECH | PENNER AVI | 1 |
| REMON MEDICAL TECH | DORON EYAL | 1 |
| Thomas Jefferson University | SUN XIAOGUANG | 1 |
Nine co-assignee pairs appear in this dataset. The strongest pairing links two entities with 6 shared records, well ahead of the next pairings at 4 and 2 shared records, suggesting most collaboration in this space is limited to a small number of long-running partnerships rather than a broad web of joint filings.
Where to take this analysis
The dataset points to specific questions worth running deeper on rather than treating this as a finished picture.
Map the software overlap in detail
Nearly half of records carry a G06F or G16H claim alongside the device claim. Pulling those pairs apart by claim language would show whether the informatics layer is being claimed defensively or as the core invention.
Explore claim structures in EurekaTrack the long tail of single-filers
Beyond the top ten assignees, dozens of companies appear with a handful of records each. Watching which of these convert into repeat filers is a leading indicator of where competitive pressure builds next.
Monitor new entrants in EurekaRe-check 2025–2026 once publications catch up
The apparent falling trend after 2019 is partly a reporting artefact of the 18-month publication lag. Revisiting the trend line in a year will give a truer read on whether filing activity has actually slowed.
Set a filing alert in EurekaCommon questions about insulin pump wireless telemetry patents
The dataset ranks 49 companies by patent family count, and the leader holds 58 records out of 206 in scope. The top five assignees together hold 59.2% of all records, and the top ten hold 80.1%, so filing activity is concentrated among a small group of incumbents rather than spread evenly. Beyond the top ten, the remaining assignees each hold only a handful of records, forming a long tail of smaller or newer entrants.
Filings peaked at 16 in 2019 and the tracked 2021-to-2024 window shows a -100% change, so on the numbers available the trend has cooled from its peak. However, publication lags filing by roughly 18 months, which means the 2025 and 2026 figures in any dataset are still incomplete and should not be read as the field going quiet. A fair read of momentum should wait until the 2025–2026 filings finish publishing.
The dominant class is A61M (devices for body fluids), appearing on 67.0% of the 206 records, followed by A61B (diagnosis and surgery) at 54.4% and A61N (electrotherapy) at 45.6%. G06F and G16H, covering digital data processing and healthcare informatics respectively, each appear on 43.7% of records, reflecting how closely the wireless data layer is tied to the physical pump claim. Because a single record can carry multiple classes, these percentages add up to well over 100%.
US8460243B2, assigned to Smiths Medical ASD, Inc. and granted in 2013, claims a combination glucose-measuring module and insulin pump held together by a quick attach-and-release mechanism, with wireless communication of glucose data between the two components for use in insulin dosing decisions. It is a representative example of the core architecture this landscape covers: a detachable sensor communicating wirelessly with a pump to inform infusion rate. Anyone designing a modular sensor-pump system with a similar quick-release and wireless-handoff structure should review this filing's specific claim language closely.
The technology composition data shows G06T (image data processing) at only 6.3% of records and G01N (material analysis and testing) at just 4.4%, both far behind the dominant device and informatics classes. That gap suggests imaging-assisted calibration and material/analyte-testing integration with wireless pump telemetry are comparatively under-claimed relative to the core hardware and data-transmission space. A first filing combining either of those branches with the established telemetry architecture would sit in less crowded prior art than a straight pump-and-sensor claim.
Research Insulin Pump Wireless Telemetry Patent Landscape in depth with Eureka
Go past this page: query the whole insulin pump wireless telemetry patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.